This multidisciplinary analysis links epidemiologic, cultural, social, and medical analyses of cancer prevention, detection, and care. The contributors demonstrate that different ethnic groups and cultures have distinct concepts of cancer prevention and control. These ideas are dynamic, shaped by personal and group histories, social networks, technologies, politics, economics, religions, linguistics, and other environmental conditions.

Cross-cultural writings about cancer make this book useful to professionals and students in the disciplines of medicine, nursing, public health, sociology, anthropology, and social welfare. The 15 articles reveal that cancer knowledge, attitudes, and behaviors are diverse cross-cultural constructs resulting from distinct experiences. Ideas and behaviors about prevention and control may be shared or individual and idiosyncratic. The book is composed of three sections: I. Cancer Beliefs and Behaviors; II. Interventions in Review; III. New Strategies for Cancer Research. The authors, including anthropologists, epidemiologists, health educators, nurses, and physicians, explicate notions of prevention and control, and assess interventions and methodologies that illustrate generally ignored successes in decreased mortality and morbidity among members of specific populations.

Childhood acute leukemias are one of the main causes of death in children aged 1 to 14 years in some countries; and unfortunately, we have been unable to prevent it. Certainly, a good parcel of it is due to the poor understanding about its etiology. This book aims to describe the most important theories and hypothesis regarding childhood acute leukemia. Written by the most outstanding researchers in the field, this book intends to contribute to a greater understanding of the etiology of this disease. It goes beyond the simple and common analysis of risk factors, which hardly allows us to draw definite conclusions. By addressing the etiology of the disease, discussing from molecular biology until epidemiology and clinical manifestations, this book will guide present and future approaches, contributing for a better clinical management of leukemia in children. The knowledge regarding etiology is a crucial step for a better evaluation, prevention and treatment of a disease. Thus, this book finally intends to provide such knowledge, allowing physicians and practitioners to a better manage of childhood acute leukemias.

This book shares the latest research and practice-oriented findings in medical sciences with a wide audience. It addresses a range of contemporary issues, often unresolved or contentious, across various medical fields, including advances in the management of hemorrhagic brain stroke. It also discusses metastatic renal cell carcinoma - a global scourge with an extremely poor long-term survival prognosis, the course and sequelae of renal cell carcinoma, as well as advances in targeted molecular therapy with sunitinib, a receptor tyrosine kinase inhibitor. Further, it examines the molecular targeting of proliferative signaling of the epidermal growth factor receptor in the first-line treatment of patients with metastatic non-small-cell lung cancer. Other articles cover clearance of toxins in hemodialyzed patients; the search for diagnostic and therapeutic markers in the connective tissue disease scleroderma; obesity linked to inappropriate dietary habit; clinical problems related to the diagnosis of sensitization to fungi and its role in asthma; and reasons for the perilous trend of avoiding basic vaccinations in children. Lastly, the book explores the rapid developments in e-health technologies that increase access to health services, particularly for the elderly. The book is intended for clinical specialists, researchers, and all allied health professionals from various fields.

The Editor of this publication is Dr Elise Olsen, Director of the Duke University Cutaneous Lymphoma Research and Treatment Center and professor of Dermatology and Oncology. In 2014, cutaneous lymphoma (CL) is considered a chronic, non-life threatening disease since the majority of patients are diagnosed at early stage, though progression to later stages does result in death from the disease. This issue covers T-cell and B-cell lymphomas, with content emphasis on Mycoides fungoides and Sezary syndrome, the two most common clinically encountered subtypes of CL. Pharmaceutical treatment of the disease is a part of each article and the issue uses the following Treatment outline: Mechanisms of action - Pharmacokinetics - Typical dosing - Response to therapy - Adverse effects - and Pearls to help management using the agent under discussion. Beyond Dermatologists, specialists who would find the information useful are Cancer specialists, Hematologists/Oncologists, Physician Assistants, Nurse Practitioners, and Pharmacists. Some of the topics, written by the word's top experts in this disease, are: Overview of primary cutaneous lymphomas and the applicable staging and classification; Pathologic diagnosis of cutaneous lymphomas; in the section on Mycosis Fungoides and Sezary Syndrome, the clinician and researcher will find such topics as Skin directed medications; Phototherapy; Systemic retinoids; Interferons; HDAC inhibiotrs, Methotrexate and praletexate, along with other chemotherapeutic agents. Also, Bone marrow transplant; Diagnosis and management of CD30+ Lymphoproliferative disorders; and Diagnosis and management of primary cutaneous B cell lymphomas.

This volume presents state-of-the-art information on each of the arms of the unfolded protein response (UPR), how their activation/repression are regulated, integrated, and coordinated, how UPR components affect cancer cell biology and responsiveness to therapeutic interventions, and how UPR components/activities offer potentially novel targets for drug discovery, repurposing, and development. The volume will provide the most recent information on the signaling and regulation of the UPR, explore examples of how the UPR and/or specific components contribute to cancer biology, and identify and explore specific examples of potently new actionable targets for drug discovery and development from within the UPR and its regulation. Unique to the volume will be a specific focus on the UPR and its role in cancer biology, as well as a discussion of the role of the UPR in drug responses and resistance in cancer.

This issue of Surgical Oncology Clinics of North America, edited by Thomas Weber, MD, is devoted to Genetic Testing in Surgical Oncology. Articles in this issue include: The Critical Importance of Timely Genetic Testing; Securing and Documenting Cancer Family History in the Age of the Electronic Medical Record; Cancer Family Registries: Vital Tools for Patient Management and Cancer Genetics Translational Research; The Genetics of Breast Cancer; The Genetics of Colorectal Cancer: HNPCC, FAP MYH, and Hamartomatous Syndromes Including Peutz-Jeghers and Jevenile Polyposis; Hereditary Gastric Cancer Syndromes; Hereditary Pancreatic Cancer Syndromes; Hereditary Melanoma: Genetics and Multidisciplinary Management; Multiple Endocrine Neoplasia: Genetics and Clinical Management; Sequence Variants of Uncertain Significance (VUS): What To Do When Genetic Testing Results Are Not Definitive; Confidentiality and the Risk of Genetic Discrimination: What Surgeons Need to Know; and A Certified Genetic Counselor: A Crucial Clinical Resource in the Management of Patients with Suspected Hereditary Solid Tumor Syndromes.

Cancers of the larynx, while survival outcomes increase, result in massive treatment damage from radiation and surgery. Patients often lose ability to speak and to eat. Preserving the larynx is a fine balance of cancer eradication, life extension, and quality of life. This issueof Otolaryngologic Clinics led by Dr Babak Sadoughi should be of interest to Otolaryngologists, Oncologists, Radiologists, and Speech Therapists. The issue approach reaches all the most important aspects of diagnosing and treating the patient with laryngeal cancer with a focus on preserving the voice in early laryngeal cancer and preserving and restoring function in advanced laryngeal cancer. Topics include: Functional Anatomy and Oncological Barriers of the Larynx; Evaluation of the Dysphonic Patient; Role of Advanced Laryngeal Imaging in Glottic Cancer; Laryngeal Function after Radiation Therapy; Management of Dysphonia after Radiation Therapy; Contemporary Surgical Management of Early Glottic Cancer; Voice Prognosis after Transoral Laser Microsurgery of the Larynx; Voice Rehabilitation after Transoral Laser Microsurgery of the Larynx; Quality of Life after Conservation Surgery for Laryngeal Cancer; Salvage Conservation Surgery of the Larynx; Airway Preservation in Ablative Laryngeal Surgery; Voice Restoration after Total Laryngectomy. A special article for Residents, written by a Resident, emphasizes essential "take home messages" for laryngeal function preservation diagnosis and treatment.

Cancer Screening and Genetics is reviewed extensively in this important Surgical Clinics of North America issue. Articles include: Cancer Genetics and Implications for Clinical Management; Epigenetics and Cancer; Screening and Early Detection of Cancer: Successes and Failures; Screening for Lung Cancer; Screening for Breast Cancer; Viral Hepatitis and Hepatocellular Cancer: How Should Patients Be Screened?; Screening for Pancreatic Cancer: Where Do We Stand?; Hereditary Colorectal Cancer: Genetics and Screening; Personalized Approach to Gastrointestinal Cancers; Screening for Colorectal Cancer; Screening for Prostate Cancer: Why the Controversy?; Gastric Cancer: East versus West-Is screening and early detection the difference?; and more!

The 7 chapters in this book have been selected from the contents of the Oncological Imaging section in Grainger & Allison's Diagnostic Radiology 6e. These chapters provide a succinct up-to-date overview of current imaging techniques and their clinical applications in daily practice and it is hoped that with this concise format the user will quickly grasp the fundamentals they need to know. Throughout these chapters, the relative merits of different imaging investigations are described, variations are discussed and recent imaging advances are detailed. Please note that the following chapters represent a portion of the oncological imaging aspects in the comprehensive 6th edition of Grainger's & Allison's Diagnostic Radiology (for example, abdominal tumours are considered in section C "Abdominal Imaging")

This issue of Hematology/Oncology Clinics of North America is devoted to Congenital and Acquired Disorders of Macrophages and Histiocytes. Guest Editors Nancy Berliner, MD and Barrett Rollins, MD have assembled a group of expert authors to review the following topics: Nosology of Langerhans Cell Histiocytosis (LCH); Cell of Origin of LCH; Genomic Changes in LCH; Clinical Treatment of LCH; Neurodegeneration in LCH; Pathogenesis of Hemophagocytic Lymphohistiocytosis (HLH); Familial HLH; HLH in Adults; Macrophage Activation Syndrome; and Stem Cell Transplant for HLH.

Cancer is a multifaceted and genomically complex disease and data obtained through high throughput technologies has provided near complete resolution of the landscape of how genomic, genetic and epigenetic mutations in cancerous cells effectively influence homeostasis of signaling networks within these cells, between cancerous cells, tumor microenvironment and at the organ level. Increasingly sophisticated information has helped us in developing a better understanding of the underlying mechanisms of cancer, and it is now known that intra-tumor genetic heterogeneity, cellular plasticity, dysregulation of spatio-temporally controlled signaling cascades, and loss of apoptosis are contributory in cancer development, progression and the development of resistance against different therapeutics. It is becoming progressively more understandable that earlier detection of pre-existing or emerging resistance against different therapeutics may prove to be helpful in personalizing the use of targeted cancer therapy. Despite the fact that there is a continuously increasing list of books, being guest edited by researchers, books on the subject are often composed of invited reviews without proper sequence and continuity and designed for a particular readership. This book progressively shifts and guides the readers from basic underlying mechanisms to translational approaches to treat cancer.

This issue of Recent Results in Cancer Research presents a comprehensive review of current understanding of chromosomal instability in cancer and of strategies to use this information for better treatment of patients with cancer. Cancer is a disease of the chromosomes, and chromosomal instability in cancer disrupts gene function by either inactivating tumor suppressor genes or activating growth-promoting oncogenes. The chromosomal basis for these aberrations is either translocations, which change the integrity of genes, or abnormal numbers of chromosomes, a condition referred to as aneuploidy, which results in abnormal gene expression levels. Such structural or numerical chromosomal aberrations are specific for distinct tumor entities. The degree of chromosomal instability and the degree of intratumor heterogeneity have profound consequences for disease outcome and for therapeutic stratification.

Drs. Robert J. Lewandowski and Matthew S. Davenport have assembled an expert panel of authors on the topic of Interventional Radiology. Articles will include: Abdominal Biopsy: Technical and Clinical Considerations; Intra-arterial Therapies for Liver Masses; Liver Ablation: Best Practice; Renal Intervention; Imaging (Findings) after Intervention; Assessing Imaging Response to Therapy; Liver Masses: Imaging Evaluation in Non-cirrhotics; Imaging in Cirrhotics: Current Evidence; Renal Masses: Imaging Evaluation; Adrenal Imaging/Intervention; The Pancreas; and more!

This issue of Hematology/Oncology Clinics, guest edited by Dr. F. Stephen Hodi, is devoted to Melanoma. Articles in this issue include: The current state of Melanoma; Understanding the Biology of Melanoma Development and Therapeutic Implications; Surgical Management of Melanoma; Targeted Therapies for Cutaneous Melanoma; Treatments for Non-cutaneous Melanoma; Resistant Mechanisms and Therapeutic Implications; The Role of the Immune System in Melanoma Development and Treatment; Vaccines and Melanoma; IL-2, Interferon, and Cytokines; Immune Checkpoint Blockade; Adjuvant Treatments, Chance for Cure in Melanoma; and Combinatorial Approach to Treatment of Melanoma.

The Guest Editors have assembled top key opinion leaders to provide current reviews on the multidisciplinary approach to the management of high-grade bladder cancer. Articles are devoted to fluorescence cystoscopy, confocal laser endomicroscopy, narrow band imaging; Novel therapeutic approaches for recurrent nonmuscle invasive bladder cancer; Trimodality therapy in bladder cancer; the data and the reality of perioperative chemotherapy in muscle invasive bladder cancer; radical transurethral resection alone, robotic or partial cystectomy or extended lymphadenectomy: Neoadjuvant paradigm for drug development in muscle invasive bladder cancer; Novel biomarkers to predict response and prognosis in localized bladder cancer; Immunotherapy in Advanced/Metastatic Urothelial Cancer ; and Adjuvant Chemotherapy in High Grade Upper Tract Urothelial Cancer.

The Editors for this 2-part issue of Otolaryngologic Clinics, Dr George Wanna and Dr Matthew Luke Carlson, envisioned a publication that reviews the evaluation and management of common ear and lateral skull base tumors. Intended audience includes Otologists, Neurotologists, General otolaryngologists and Neurosurgeons alike. The development of management of lateral skull base tumors has been rapid, in the past 40 years there has been a tremendous shift toward conservative therapy for benign lesions. Focused chapters review specific pathologies plus a chapter focused on stereotactic radiotherapy. Topics written by reputed leaders in the field of Otology and skull base tumors include: Imaging of temporal bone lesions; Squamous cell carcinoma of the temporal bone; Glomus tympanicum; Adenomatous tumors of the middle ear; Intralabyrinthine schwannomas; Vestibular schwannoma; Neurofibromatosis2 (including ABI and CI); Non-schwannoma tumors of the CPA; Glomus jugulare; Endolymphatic sac tumors; Non-paraganglioma jugular foramen tumors; Primary tumors of the facial nerve; Cholesterol granuloma and other petrous apex lesions; Stereotactic radiosurgery for tumors of the lateral skull base; Pediatric temporal bone malignancy; and Historical perspective on evolution in management of lateral skull base tumors.

This issue of Hematology/Oncology Clinics of North America is devoted to Pancreatic Cancer. Guest Editor Brian Wolpin, MD has assembled a group of expert authors to review the following topics: Biology and genetics of pancreatic adenocarcinoma; Mouse models of pancreatic adenocarcinoma; Epidemiology and inherited predisposition for sporadic pancreatic adenocarcinoma; Familial pancreatic adenocarcinoma; Imaging and endoscopic approaches to pancreatic cancer; Diagnosis and management of pancreatic cystic neoplasms; Surgical management of pancreatic cancer; Peri-operative therapy for surgically resectable pancreatic adenocarcinoma; Diagnosis and management of borderline resectable pancreatic adenocarcinoma; Treatment approaches to locally advanced pancreatic adenocarcinoma; Therapeutic approaches for metastatic pancreatic adenocarcinoma; Supportive and end-of-life care for patients with pancreatic adenocarcinoma; and Novel therapeutics for pancreatic adenocarcinoma.

This volume presents state of the art of methods that can be useful for both basic and translational researchers to conduct chemoprevention preclinical studies. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Cancer Chemoprevention: Methods and Protocols aims to ensure successful results in the further study of this vital field.

The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, wound healing disorders, and more. Efforts to understand the molecular basis, both for inhibition and induction, have yielded fascinating results. Originally published by Bentham and now distributed by Elsevier, Anti-Angiogenesis Drug Discovery and Development, Volume 2 is an compilation of well-written reviews on various aspects of the anti-angiogenesis process. These reviews have been contributed by leading practitioners in drug discovery science and highlight the major developments in this exciting field in the last two decades. These reader-friendly chapters cover topics of great scientific importance, many of which are considered significant medical breakthroughs, making this book excellent reading both for the novice as well as for expert medicinal chemists and clinicians.

This book provides the reader with a multidisciplinary approach that is state of the art and reflects input from the European Neuroendocrine Tumor Society and the North American Neuroendocrine Tumor Society. In particular, the text focuses on the pathophysiology of neuroendocrine tumors and includes a comprehensive review of the most recent developments in understanding the complex hormone and receptor signaling that is important for the future development of potent pharmacological treatments. The volume reviews the pathological grading and staging systems providing useful clinical information for the treating clinician as well as a useful reference for pathologists. The clinical management of neuroendocrine tumors is reviewed enabling the treating physician to understand the diagnostic approaches to differentiating the various types of neuroendocrine tumors. In addition, the treatments are reviewed in great detail and include novel radiological, surgical, and chemotherapeutic approaches. The reader will utilize this book as both a comprehensive and quick reference guide through the use of diagnostic and treatment algorithms. Written by international experts in their particular field of study, Management of Pancreatic Neuroendocrine Tumors will be of great value to medical oncologists, endocrinologists, gastroenterologists, pathologists, surgeons, and diagnostic and interventional radiologists.

1. Prevention and Early Detection of Lung Cancer - Clinical Aspects.- 2. Smoking Prevention and Cessation.- 3. Clinical Pharmacology of Vitamin A and Retinoids.- 4. Early Lung Cancer Detection.- 5. Molecular Abnormalities in the Sequential Development of Lung Carcinoma.- 6. Application of In Situ PCR and In Situ Hybridization to the Characterization of Lung Cancers.- 7. Tumor Stroma Formation in Lung Cancer.- 8. Tumor Angiogenesis: Basis for New Prognostic Factors and New Anticancer Therapies.- 9. Cell Cycle Regulators and Mechanisms of Growth Control Evasion in Lung Cancer.- 10. Molecular Genetics of Lung Cancer.- 11. Neuropeptides, Signal Transduction and Small Cell Lung Cancer.- 12. In Vitro Analysis of Bombesin/Gastrin-Releasing Peptide Receptor (bb2) Ligand Binding and G-Protein Coupling.- 13. DNA Methylation Changes in Lung Cancer.- 14. K-ras Mutations as Molecular Markers of Lung Cancer.- 15. Sheep Lung Adenomatosis: A Model of Virally Induced Lung Cancer.- 16. Retinoic Acid Receptor ss An Exploration of its Role in Lung Cancer Suppression and its Potential in Cancer Prevention.- 17. Cytochrome P450 Polymorphisms: Risk Factors for Lung Cancer?.- 18. Glutathione S-Transferases and Lung Cancer Risk.- 19. The p53 Tumor Suppressor Gene in Lung Cancer: From Molecular to Serological Diagnosis.- 20. Endoscopic Localization of Preneoplastic Lung Lesions.- 21. Antigen Retrieval Improves hnRNP A2/B1 Immunohisto-chemical Localization in Premalignant Lesions of the Lung.- 22. Molecular Pathological Mechanisms in NSCLC and the Assessment of Individuals with a High Risk of Developing Lung Cancer.- 23. Chemoprevention of Lung Cancer.- 24. Regional Delivery of Retinoids: A New Approach to Early Lung Cancer Intervention.- 25. Natural Inhibitors of Carcinogenesis.- 26. Gene Delivery to Airways.- 27. Lung Cancer Prevention: The Point of View of a Public Health Epidemiologist.- 28. Biomarkers as Intermediate Endpoints in Chemoprevention Trials: Biological Basis of Lung Cancer Prevention.- 29. Biological Tools for Mass Screening.- 30. Optimization of the Use of Biological Samples for the Prospective Evaluation of Preneoplastic Lesions.